July 6 (Reuters) - Kazia Therapeutics Ltd (KZA) :
- KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY
- KAZIA THERAPEUTICS LTD - FURTHER DATA FROM ONGOING PHASE 1 STUDY IS EXPECTED IN 1Q CY2024